Cencora (COR) closed at $349.38 on November 12, 2026, down 0.1% from the previous close, on volume of 927,160 shares (30-day average 1,278,518).
Data as of November 12, 2026.
12-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 21, 2026 | Call with Delta Hedge | 15-Jan-27 390 C +13,500 Stock | 750 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Cencora (COR) Receives a Hold from Bank of America Securities
TipRanks (Tue, 10-Nov 9:55 AM ET)
J.P. Morgan Sticks to Its Buy Rating for Cencora (COR)
TipRanks (Tue, 10-Nov 7:36 AM ET)
Cencora Announces New Organizational and Reporting Structure to Enhance Visibility and Focus
Business Wire (Wed, 4-Nov 6:35 AM ET)
Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results
Business Wire (Wed, 4-Nov 6:35 AM ET)
Globe Newswire (Mon, 2-Nov 11:20 AM ET)
Globe Newswire (Mon, 26-Oct 2:17 PM ET)
Gabelli To Host 8th Annual Healthcare Symposium
Globe Newswire (Mon, 26-Oct 8:00 AM ET)
Globe Newswire (Wed, 21-Oct 11:28 AM ET)
Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology
Business Wire (Wed, 21-Oct 7:30 AM ET)
Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
Business Wire (Fri, 2-Oct 8:00 AM ET)
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices and global specialty drug logistics (World Courier). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Cencora trades on the NYSE stock market under the symbol COR.
As of November 12, 2026, COR stock price declined to $349.38 with 927,160 million shares trading.
COR has a beta of -0.07, meaning it tends to be less sensitive to market movements. COR has a correlation of 0.00 to the broad based SPY ETF.
COR has a market cap of $66.67 billion. This is considered a Large Cap stock.
Last quarter Cencora reported $88 billion in Revenue and $4.66 earnings per share. This beat revenue expectation by $393 million and exceeded earnings estimates by $.09.
In the last 3 years, COR traded as high as $377.54 and as low as $191.11.
The top ETF exchange traded funds that COR belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
COR has underperformed the market in the last year with a return of -3.6%, while SPY returned +12.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in COR shares. However, COR has outperformed the market in the last 3 month and 2 week periods, returning +4.8% and +7.7%, while SPY returned -1.5% and -2.0%, respectively. This indicates COR has been having a stronger performance recently.
COR support price is $344.55 and resistance is $355.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COR shares will trade within this expected range on the day.
